Regeneus Ltd Stock Market Press Releases and Company Profile
Edison Investment Report Issued
Edison Investment Report Issued

Sydney, Sep 11, 2017 AEST (ABN Newswire) - The following investment report by Edison titled 'Preparing for a clinical licence deal in Japan' has been published.

Please contact or connect with Regeneus via social media platforms below if you'd like further information.

To view the Edison Report, please visit:
http://abnnewswire.net/lnk/ZT58EC4E


About Regeneus Ltd

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.

https://plus.google.com/108721050557390681250 https://twitter.com/Regeneus https://www.facebook.com/pages/Regeneus/110433905646491 https://www.youtube.com/user/Regeneus http://www.linkedin.com/company/regeneus-ltd?trk=top_nav_home abnnewswire.com 


Contact

Sandra McIntosh
Company Secretary and Investor Relations

Tel: +61 2 9499 8010
Fax: +61 2 9499 8020
Mob: +61 450 253 059
Email: investors@regeneus.com.au



ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 19) (Last 30 Days: 62) (Since Published: 6881)